Bio-Techne Corp (TECH) : Bio-Techne Corp (TECH) had a healthy money flow of $0.23 million into the stock during the Thursdays trading session. The value of bullish trades on upticks was $0.24 million, whereas, investors only sold shares worth $0.01 million on downticks. The stock closed the day with an up-down ratio of 21.25.The money flow in the block trades to the tune of $0.1 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0.1 million worth of transactions were on upticks. Bio-Techne Corp (TECH) stock slid $1.16 intraday and traded at 113.17, a change of -1.01% over previous days close. However, for the week, the company shares are -1.74% compared to previous weeks close.
The stock has recorded a 20-day Moving Average of 0.22% and the 50-Day Moving Average is 2.9%. Shares have rallied 13.68% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $117.42 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $111.29 and the 200 Day Moving Average price is recorded at $96.27.
Bio-Techne Corp (NASDAQ:TECH): The stock opened at $114.50 on Thursday but the bulls could not build on the opening and the stock topped out at $114.50 for the day. The stock traded down to $111.72 during the day, due to lack of any buying support eventually closed down at $111.88 with a loss of -2.14% for the day. The stock had closed at $114.33 on the previous day. The total traded volume was 261,137 shares.
In an insider trading activity, Lucas Roger C, director of Bio-Techne Corp, unloaded 100 shares at an average price of $92.4 on April 20, 2016. The total amount of the transaction was worth $9,240, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Bio-Techne Corporation (Bio-Techne), formerly Techne Corporation, develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins, including cytokines and growth factors, antibodies, related immunoassays, biologically active small molecules, and other reagents to the research, diagnostics and clinical controls markets.